ARCA biopharma (ARCA biopharma) Cash-to-Debt

: 183.49 (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ARCA biopharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 183.49.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ARCA biopharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for ARCA biopharma's Cash-to-Debt or its related term are showing as below:

ABIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 119.98 Med: No Debt Max: No Debt
Current: 183.49

During the past 13 years, ARCA biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 119.98. And the median was No Debt.

ABIO's Cash-to-Debt is ranked better than
82.6% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs ABIO: 183.49

ARCA biopharma Cash-to-Debt Historical Data

The historical data trend for ARCA biopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ARCA biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

119.98

139.32

151.59

183.49

ARCA biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																151.59	155.92	165.25	171.82	183.49

Competitive Comparison

For the Biotechnology subindustry, ARCA biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARCA biopharma Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Cash-to-Debt falls into.

ARCA biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ARCA biopharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	37.431	/	(0	+	0.204)
	=	183.49

ARCA biopharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	37.431	/	(0	+	0.204)
	=	183.49

ARCA biopharma (NAS:ABIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

ARCA biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma (ARCA biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HQ10:Germany

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

http://www.arcabiopharma.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Executives

James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp	10 percent owner, other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp	other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver	other: See Remarks	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff	officer: S.V.P., General Counsel	8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker	officer: Chief Financial Officer	10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer	officer: Chief Operating Officer	C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby	officer: VP, Finance	11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell	10 percent owner
David M Mott	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett	10 percent owner
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202